IXC 1.43% 7.1¢ invex therapeutics ltd

Ann: Invex to close IIH Evolve Phase III Clinical Trial, page-39

  1. 1,375 Posts.
    lightbulb Created with Sketch. 281
    The raise of $20+ million post phase II trial, and Tattarang as a sub holder (along with Sinclair as a genuine leader in the field) did not scream red flags but obviously there was something there we all missed
    Last edited by BalkanBroker: 22/08/23
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
7.1¢
Change
0.001(1.43%)
Mkt cap ! $5.335M
Open High Low Value Volume
7.1¢ 7.3¢ 7.1¢ $2.546K 35.86K

Buyers (Bids)

No. Vol. Price($)
1 14158 7.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 5000 1
View Market Depth
Last trade - 14.37pm 31/07/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.